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ABSTRACT
Although microRNAs (miRNAs) are important regu-
lators of gene expression, the transcriptional regu-
lation of miRNAs themselves is not well understood.
We employed an integrative computational pipeline
to dissect the transcription factors (TFs) responsible
for altered miRNA expression in ovarian carcinoma.
Using experimental data and computational predic-
tions to define miRNA promoters across the human
genome, we identified TFs with binding sites signifi-
cantly overrepresented among miRNA genes over-
expressed in ovarian carcinoma. This pipeline
nominated TFs of the p53/p63/p73 family as candi-
date drivers of miRNA overexpression. Analysis of
data from an independent set of 253 ovarian carcin-
omas in The Cancer Genome Atlas showed that p73
and p63 expression is significantly correlated with
expression of miRNAs whose promoters contain
p53/p63/p73 family binding sites. In experimental
validation of specific miRNAs predicted by the ana-
lysis to be regulated by p73 and p63, we found that
p53/p63/p73 family binding sites modulate promoter
activity of miRNAs of the miR-200 family, which are
known regulators of cancer stem cells and epithe-
lial–mesenchymal transitions. Furthermore, in chro-
matin immunoprecipitation studies both p73 and
p63 directly associated with the miR-200b/a/429
promoter. This study delineates an integrative ap-
proach that can be applied to discover transcrip-
tional regulatory mechanisms in other biological
settings where analogous genomic data are
available.
INTRODUCTION
Regulation of gene expression at the post-transcriptional
level is governed in part by microRNAs (miRNAs), which
are approximately 22 nucleotide non-protein-encoding
RNAs that modulate the stability and/or translation of
messenger RNAs (mRNAs) via partially complementary
base-pairing interactions (1). Most microRNAs are
transcribed by RNA polymerase II (2), and miRNA ex-
pression can be regulated by transcription factor (TF)
*To whom correspondence should be addressed. Tel: 206 667 5165; Fax: 206 667 4023; Email: mtewari@fhcrc.org
The authors wish it to be known that, in their opinion, the ﬁrst three authors should be regarded as joint First Authors.
Present addresses:
Deepayan Sarkar, Indian Statistical Institute, Delhi Centre, 7, S. J. S. S. Marg, New Delhi-110016, India.
Andrew K. Godwin, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Robert Gentleman, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Published online 14 September 2011 Nucleic Acids Research, 2012, Vol. 40, No. 2 499–510
doi:10.1093/nar/gkr731
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.binding sites present in their promoters (3–7). However,
for the majority of miRNAs, promoters have not been
deﬁned and the TF binding sites upstream of these
miRNA loci have not been experimentally tested.
Dysregulation of miRNA expression is common in
human disease and contributes to pathology, since
miRNAs regulate signiﬁcant disease-relevant processes
such as cell division, differentiation, and apoptosis (8,9).
In addition, in certain cancer contexts, the pattern of
miRNA expression captures important features of the de-
velopmental origin of cancers (10) and may predict the
course of disease (11). However, the mechanisms under-
lying miRNA dysregulation are not clear, in part because
the transcriptional regulation of most miRNAs is not well
characterized.
In this study, we implemented an integrative computa-
tional approach to dissect the transcriptional regulation of
miRNAs. We focused on the dysregulation of miRNAs in
ovarian carcinoma of the serous histologic sub-type,
which has a high mortality and accounts for approxi-
mately two-thirds of ovarian carcinomas. Although a
subset of miRNAs dysregulated in ovarian carcinomas is
associated with changes in genomic copy number and epi-
genetic modiﬁcations, for many miRNAs additional,
unknown mechanisms appear to contribute to the re-
programming of miRNA expression (12,13). We therefore
sought to discover the TFs that may drive the dysregula-
tion of miRNAs in ovarian carcinoma. We implemented a
computational pipeline to annotate miRNA transcription
start sites (TSS) and putative promoter regions, and then
to identify the TFs with binding sites enriched in the pro-
moters of overexpressed miRNAs in ovarian carcinoma.
This approach yields putative regulatory interactions
between TFs and miRNA promoters for subsequent ex-
perimental validation.
We report here that the best candidate driver of miRNA
overexpression in ovarian carcinoma is the p53/p63/p73
family of TFs. Although p53 has been shown to trans-
activate several miRNAs, including the miR-34 family
(14–17), the transcriptional regulation of miRNA genes
by p73 and p63 has not been well-described. Further
analysis using data from The Cancer Genome Atlas
(TCGA) suggested that, in ovarian carcinoma, p73
and p63 are primarily responsible for the altered expres-
sion of miRNAs with p53 family binding sites. We experi-
mentally validated our approach by conﬁrming that
p73 and p63 directly regulate transcription of the
miR-200 family, a novel target predicted by our analysis
that is an important regulator of epithelial–mesenchymal
transitions (EMTs) and of the cancer stem cell pheno-
type (18–22).
This study illustrates how an integrative computational
analysis can identify new regulatory interactions between
TFs and miRNAs. We also provide a resource by deﬁning
putative miRNA promoters and associating TF binding
sites with these miRNA promoters on a genome-wide
scale, and we discuss how our approach is broadly applic-
able to dissect TF–miRNA regulatory networks in other
systems where miRNA expression data from distinct
physiologic states are available.
MATERIALS AND METHODS
Clinical materials
Normal primary human ovarian surface epithelial (HOSE)
cell and serous ovarian carcinomas from which RNA was
analyzed in this study have been previously described (23),
and are described in Supplementary Data. HOSE speci-
mens were obtained under a protocol that was approved
by the Research Review Committee and Internal Review
Board at the Fox Chase Cancer Center. All ovarian car-
cinoma tissue specimens were collected by the Paciﬁc
Ovarian Cancer Research Consortium Repository under
a protocol approved by the Fred Hutchinson Cancer
Research Center Institutional Review Board.
Analysis of miRNA microarray data generated in the
current study
We analyzed miRNA microarray data generated on a
locked nucleic acid (LNA) probe-based platform designed
to proﬁle 480 human miRNAs (Exiqon, Inc.) (23). Array
quality control and data normalization was performed as
previously described (23). We deﬁned expressed miRNAs
as the miRNAs expressed in at least two of the four
normal or at least four of the 16 serous ovarian carcin-
omas. Non-speciﬁc ﬁltering was performed as previously
described (23), and genes that showed low variabil-
ity across samples were removed from the analysis, which
yielded 181 genes for downstream analyses. Differentially
expressed miRNAs were identiﬁed by considering miRNAs
to be over- or underexpressed in carcinoma compared to
normal if log2 fold change was greater than 1.0 and
adjusted P<0.01.
Identiﬁcation of TFs commonly expressed in serous
ovarian carcinoma
We analyzed data from Hendrix et al. (24), where
Affymetrix GeneChip Human Genome U133 Array Set
HG-U133A microarrays were used to proﬁle gene expres-
sion across a panel of 4 normal ovaries and 41 serous
ovarian carcinoma tissues. The carcinoma tissues com-
prised the following stages: Stage IA (n=1), Stage IC
(n=3), Stage II (n=2), Stage IIC (n=2), Stage III
(n=2), Stage IIIB (n=1), IIIC (n=25), IIID (n=1)
and IV (n=5) and the following grades:
well-differentiated (n=2), moderately differentiated
(n=5), poorly differentiated (n=18), grade information
not available (n=16). All samples were selected to
contain at least 70% malignant epithelial cells. We con-
sidered genes to be expressed if they showed expression [as
determined by Affymetrix PMA (Present/Marginal/
Absent) calls] in at least 2 out of 4 normal samples or 8
out of 41 carcinoma samples. We identiﬁed 83 TFs ex-
pressed in normal ovary and/or serous ovarian carcinoma
tissue specimens by intersecting expressed genes with all
TFs in tfbsConsFactors ﬁles downloaded from the UCSC
genome browser (25,26). Out of these 83 TFs, 79 corres-
ponded to binding sites found upstream of miRNAs
overexpressed in ovarian carcinoma.
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TF binding sites
miRNA coordinates were downloaded from miRBase
(version 10) (27) and used to map miRNAs to their
genomic locations as described in Supplementary Data.
To assign TSS for each miRNA locus, we used RefSeq,
AceView, expressed sequence tags (ESTs) and Eponine
predictions downloaded from the UCSC genome
browser (hg 18 version of the genome assembly) (26). If
both 50 and 30 ESTs were available from the same clone
and formed a transcript containing the miRNA, the
miRNA was considered expressed by this transcript and
its TSS was the 50-end of the EST.
We examined the putative promoters of each miRNA/
miRNA locus for conserved TF binding sites deﬁned in
the UCSC ﬁles tfbsConsSites and tfbsConsFactors (26),
as described in Supplementary Data. The conservation
of binding sites is based on human/mouse/rat multiple
alignments and the score is computed using the Transfac
Matrix Database (v7.0) (28).
Enrichment of TF binding sites in promoters of
overexpressed miRNA loci
We performed a Fisher’s exact test for each of the 79 ex-
pressed TFs to compare the number of TF binding sites
in the promoters of overexpressed miRNA loci versus
control miRNA loci. To assess the false discovery rate,
predicted Q-values were estimated from P-values
(derived from Fisher’s exact test) by using the ‘Q-value’
package in R (29).
Correlations between expression of TFs and expression of
miRNAs in TCGA data set
We analyzed data from 253 serous ovarian carcinoma spe-
cimens from TCGA. Serous ovarian carcinoma tissue spe-
cimens in TCGA are generally from patients with
advanced stage and high-grade disease. Clinical data on
stage and grade was available on 217 of the 253 specimens
we studied, and conﬁrmed that the vast majority of these
were high-grade (202 were poorly differentiated and 13
were moderately differentiated) and advanced stage
[Stage IIB (n=2), Stage IIC (n=4), Stage IIIA (n=2),
Stage IIIB (n=9), Stage IIIC (n=161) and Stage IV
(n=39)]. Data on percentage malignant epithelium was
available for 202 of the 253 specimens we studied: >75%
malignant epithelial cells (n=150 specimens), 50%
and<75% (n=43 specimens),<50% (n=9 specimens).
To derive correlations between TF and miRNA expres-
sion, we retrieved Agilent gene expression microarray
and miRNA microarray data from the TCGA for 253
serous ovarian carcinomas, for which both gene expres-
sion (run on AgilentG4502A_07_3) and miRNA expres-
sion proﬁling data were available (http://cancergenome.
nih.gov/index.asp). Agilent Level 1 microarray expression
data were used for both miRNA and mRNA analyses. We
used 447 miRNAs for calculating correlations; all of these
miRNAs had at least one TF binding site associated with
their promoters as determined by our method. All TCGA
Level 1 ﬁles used to calculate correlations are listed in
Supplementary Table S1. Correlation between the expres-
sion of the miRNAs and TFs was assessed by calculating
Pearson correlation coefﬁcients. Bioconductor packages
‘limma’ and ‘ltm’ were used to process the raw signal
data and to calculate P-values for correlation between
the expression of miRNAs and TFs, respectively (30,31).
Sequencing of TP53
All coding and ﬂanking regulatory regions for exons 4-10
of TP53 were sequenced as previously described (32).
Cell culture
The 2008 ovarian carcinoma cell line was maintained in
RPMI (Invitrogen) with 10% fetal bovine serum (Atlanta
Biologicals) under 5% CO2. All transfections were per-
formed using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed on 2008
ovarian carcinoma cells as previously described (33).
Sheared chromatin was incubated with 12mg of anti-
body overnight at 4 C and then incubated with 40ml pre-
washed Protein G agarose beads (Millipore). Antibodies
used for immunoprecipitation included 4A4 (Santa Cruz)
for p63, 259A (Imgenex) for p73, and normal mouse IgG
(Santa Cruz) to control for non-speciﬁc binding.
Quantitative PCR (qPCR) was performed as described
in Supplementary Data using the primers listed in
Supplementary Table S2. Triplicate immunoprecipitations
were performed using each antibody, using independent
batches of chromatin.
Promoter assays
Fireﬂy luciferase promoter activity reporter plasmids
were generated by PCR ampliﬁcation of the region of
interest from human genomic DNA (BioLine) followed
by subcloning into the MluI and BglII sites of the
pGL3-Enhancer vector (Promega), as described in
Supplementary Data. Primers used are in Supplementary
Table S3. To assay promoter activity, 2008 cells were
plated in 96-well plates at 8 10
3 cells/well 24h prior to
transfection. The cells were co-transfected with 100ngof
each ﬁreﬂy luciferase promoter reporter vector, or
pGL3-Enhancer as a control, and 25ng of pRL-TK
(Promega). Twenty-four hours after transfection, ﬁreﬂy
and Renilla luciferase activity was measured with the
Dual-Luciferase Reporter Assay System (Promega).
Promoter activity was calculated as the ratio of ﬁreﬂy to
Renilla luciferase signal.
RESULTS
Overview of computational pipeline for the identiﬁcation
of TFs regulating miRNA expression
We implemented a computational pipeline to study
the transcriptional regulation of miRNA expression
(Figure 1). Brieﬂy, the pipeline starts with miRNA differ-
ential expression data as input and classiﬁes miRNAs into
Nucleic AcidsResearch, 2012, Vol.40,No. 2 501two categories: miRNAs that are overexpressed in the
samples of interest and control miRNAs that are ex-
pressed but not overexpressed. Putative promoters of
both the overexpressed and control miRNAs are then
deﬁned via genomic mapping and annotation of TSS
using a series of criteria described below. After identifying
the TFs expressed in the samples based on mRNA expres-
sion data, the number of predicted binding sites for each
expressed TF in the promoters of both the overexpressed
miRNA and control miRNA loci is determined.
The output of the pipeline is TFs with binding sites
overrepresented in the promoters of the overexpressed
miRNAs, and these regulatory predictions can then be
experimentally validated.
Identiﬁcation of a set of miRNAs commonly differentially
expressed in serous ovarian carcinoma
As input to our pipeline, we deﬁned miRNAs that are
differentially expressed in serous ovarian carcinomas com-
pared to normal specimens. To avoid bias, we used mul-
tiple studies to identify miRNAs that are commonly
altered in ovarian carcinoma. We previously proﬁled
miRNA expression in primary serous ovarian carcinomas
from 16 individuals and in cultured normal human
ovarian surface epithelial (HOSE) cells from 4 other indi-
viduals using miRNA microarrays (23). We analyzed that
data set here to identify miRNAs signiﬁcantly dysregu-
lated in serous ovarian carcinoma as compared to
normal. We found 43 miRNAs to be overexpressed and
20 to be underexpressed in ovarian carcinoma (log2
fold change >1.0 and adjusted P<0.01) (Supplementary
Table S4). We then compared the results of this analysis
and six other ovarian carcinoma miRNA proﬁling studies
(13,34–38). We found 30 miRNAs to be signiﬁcantly
overexpressed in two or more of the entire set of seven
studies (Supplementary Table S5), which should provide a
more reliable list of miRNAs commonly overexpressed in
serous ovarian carcinomas. We also identiﬁed a set of
18 commonly underexpressed miRNAs (Supplementary
Table S6), although these did not yield statistically signiﬁ-
cant overrepresentation of any speciﬁc TF binding sites in
subsequent analysis and are therefore not discussed
further.
In order to deﬁne a set of control miRNAs for compari-
son, we used data from our microarray analysis of ovarian
carcinoma and normal specimens to identify 238 expressed
miRNAs, which includes the 30 commonly overexpressed
miRNAs deﬁned above. We then converted this list of
expressed miRNAs to a list of miRNA loci, where each
locus corresponds to a single promoter, which may drive
expression of multiple miRNAs. Speciﬁcally, we mapped
each miRNA to its genomic position, and miRNAs that
are encoded at multiple locations were assigned to each
locus separately. Because many miRNAs are found in
clusters in single polycistronic transcripts (39,40), we anno-
tated all miRNAs within a genomic cluster as a single
locus. After accounting for the expansion of the number
of miRNA locations as a result of miRNAs encoded at
multiple loci, and contraction of this number because
of miRNAs in clusters with shared promoters, the 238
miRNAs corresponded to 151 loci representing a miRNA
or miRNA cluster that is expressed in serous ovarian carcin-
omas and/or normal samples (Supplementary Table S7).
We divided the 151 loci into two classes: those that encode
overexpressed miRNAs and those that do not. If a single
miRNA within a cluster was overexpressed, the entire
miRNA locus was classiﬁed into the overexpressed class
for the purpose of this analysis. From this approach, we
annotated 30 loci (miRNAs or miRNA clusters) that were
overexpressed in serous ovarian carcinomas, and we used
overexpressed
loci
control
loci
miRNA differential expression data
(ovarian carcinoma and normal
HOSE miRNA profiling)
Annotate miRNA loci
(single miRNAs or miRNA clusters)
Identify TSS and define promoters
Identify binding sites for
transcription factors expressed in
ovarian carcinoma or normal tissue
Transcription factor binding sites
over-represented in promoters of
overexpressed miRNAs
(q-value <0.05)
Test hypotheses generated from
computational predictions
Correlations between
transcription factor
and miRNA expression
in vivo
experimental
validation
Classify loci as commonly overexpressed
or control (expressed)
Figure 1. Analysis pipeline for identifying candidate TFs responsible
for miRNA overexpression. MicroRNA and mRNA expression
proﬁling data were used to identify TF binding sites overrepresented
in the promoters of miRNAs overexpressed in ovarian carcinoma. TF
binding sites were based upon Transfac position weight matrices. (TSS,
transcriptional start site; HOSE, human ovarian surface epithelial cells).
502 Nucleic Acids Research, 2012,Vol. 40,No. 2the remaining 121 loci as the control set in all further
analyses (Supplementary Table S8).
Annotation of miRNA TSSs and identiﬁcation of
candidate TFs controlling miRNA expression
To deﬁne putative promoter regions for subsequent
analysis, we ﬁrst annotated the TSS of each overexpressed
or control miRNA locus (Supplementary Table S7). We
found 43% of miRNAs to be located within and in the
same orientation as a RefSeq gene (41). The TSS for these
miRNAs was assumed to be the same as for the host gene,
as it has been shown that miRNAs within host genes are
generally co-transcribed from a shared promoter (42,43).
For miRNA genes that did not match to RefSeq, we used
AceView, which provides comprehensive transcriptional
evidence from full length cDNAs and ESTs (44), to
identify the TSS of 38% of the miRNAs. We next used
predictions by Eponine (45) to deﬁne the TSS of 7% of the
miRNAs and EST clones to locate the TSS of 3% of the
miRNAs. For the remaining 9% of miRNAs whose TSS
could not be found by the above methods, the position
500bpupstream of the miRNA was taken as the TSS. In
the case of miRNAs that lie in genomic clusters, the TSS
of the most 50 miRNA was assigned to all miRNAs in the
cluster, because such miRNAs are expressed as a single
primary transcript from a shared promoter (40).
To ensure our analysis would involve only TFs
commonly expressed in serous carcinoma and/or normal
ovarian tissue, we used mRNA microarray data from
serous ovarian carcinomas and from normal ovarian tis-
sues available in the Gene Expression Omnibus
(GSE6008) (24) to identify 79 TFs expressed in normal
ovary and/or serous ovarian carcinomas. For each of the
151 miRNA (or miRNA cluster) loci identiﬁed above, we
examined a region extending from 5000bpupstream to
500bpdownstream of the TSS for predicted TF binding
sites (Supplementary Table S8). If a miRNA was less than
500bpdownstream from the TSS, we instead used the
distance between the miRNA and TSS for the downstream
boundary of the region of interest. We only included
binding sites conserved between human, mouse and rat,
as annotated by the UCSC genome browser (26), for the
79 expressed TFs.
To determine which TFs are likely to drive miRNA
overexpression in ovarian carcinoma, we performed a
Fisher’s exact test for each of the 79 TFs to compare the
number of binding sites in the putative promoters of the
30 overexpressed miRNA loci with the number of sites for
the 121 control miRNA loci (Supplementary Table S9).
We found an overrepresentation of binding sites for the
tumor protein 53 (p53) family, early growth response 2
(EGR2), and SP1 in the promoters of miRNAs over-
expressed in serous ovarian carcinoma [Q-value<0.05,
(29); Table 1]. The most signiﬁcant Q-value, 0.005,
was found for the p53 family, which consists of three
proteins (i.e. p53, p63 and p73) that recognize the same
consensus binding site (46,47). We identiﬁed 15 p53 family
binding sites among the 30 overexpressed miRNA
promoter loci versus 17 such sites in the 121 control
miRNA promoter loci (Table 1). Thus, this analysis
suggests that the three members of the p53 family, as
well as EGR2 and SP1, may be drivers of miRNA
dysregulation in serous ovarian carcinoma.
Correlation between expression of TFs and expression of
miRNAs in TCGA data
To determine if expression of the candidate miRNA TFs
we identiﬁed correlates with expression of miRNAs with
binding sites for those TFs, next we employed a larger,
independent data set from TCGA, which provides com-
prehensive genomic proﬁling data from high-grade serous
ovarian carcinomas. We selected samples from TCGA for
which both miRNA and mRNA data were available for
the same carcinoma tissue specimen. There were 253 such
samples available. We calculated Pearson correlations
between the expression of each of the ﬁve TFs identiﬁed
above and the expression of each of 447 miRNAs in the
253 TCGA samples. We then compared correlation coef-
ﬁcients between the miRNAs whose promoters contain
binding sites for a given TF and the remaining miRNAs
lacking binding sites. We found no signiﬁcant difference in
the correlation of SP1 and miRNAs with or without SP1
binding sites (data not shown). However, the remaining
four TFs (i.e., TP53, TP63, TP73, and EGR2) showed
signiﬁcantly higher expression correlations with miRNAs
bearing their respective binding sites versus those without
(P<0.01, t-test) (Figure 2). This analysis suggests that our
pipeline yields functional regulators of miRNA expres-
sion. Interestingly, we found signiﬁcant negative correl-
ations between the expression of both EGR2 probes and
the expression of miRNAs with EGR2 binding sites,
which suggests that EGR2 may serve as a transcriptional
repressor (Figure 2D).
Table 1. TF binding sites enriched in promoters of miRNAs
overexpressed in serous ovarian carcinoma
TF binding
site
Promoters of
overexpressed
miRNA
Promoters of
expressed
miRNAs
P-value Q-value
With
site
Without
site
With
site
Without
site
p53/p63/p73 15 15 17 104 6.83E-05 0.0054
EGR2 10 20 9 112 0.0006 0.0246
SP1 10 20 10 111 0.0011 0.0283
NFKB1 10 20 16 105 0.0145 0.2856
RELA 9 21 14 107 0.0206 0.2954
NR2F1 6 24 7 114 0.0233 0.2954
EGR3 8 22 11 110 0.0262 0.2954
PAX4 14 16 31 90 0.0429 0.4036
XBP1 7 23 10 111 0.0460 0.4036
MicroRNAs were classiﬁed into 30 loci overexpressed in ovarian car-
cinoma and a control group of 121 loci expressed in carcinoma and/or
normal HOSE samples. The number of promoters with binding sites for
a given TF was compared between the two classes. A Fisher’s exact test
was performed for each of the 79 TFs that are expressed in carcinoma
and/or normal samples. P-values computed by Fisher’s exact test were
converted to Q-values. TFs with P<0.05 are shown, while those with
Q<0.05 are in bold.
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that showed positive, signiﬁcantly higher correlations
with miRNAs bearing p53 family binding sites than
those without (Figure 2A–C). Three out of seven TP63
probes and one out of three TP53 probes showed lower
correlations that were not statistically signiﬁcant (data not
shown), which may be related to sequence-speciﬁc vari-
ation in probe performance. Of the three members of
the p53 family, TP73 expression showed the strongest
positive correlations with miRNAs bearing p53 family
binding sites (Figure 2C). Taken together, these results
suggest that members of the p53 family, and in particular
p73, may drive the overexpression of a panel of miRNAs
in ovarian carcinoma.
Overexpression of miRNAs with p53 binding sites in their
promoters is not associated with the mutational status of
TP53 in serous ovarian carcinomas
While expression of p53 mRNA appeared to correlate
with miRNA expression, regulation of p53 occurs primar-
ily at the protein level. Therefore, we sought to determine
whether changes in the activity of the p53 protein may
affect the expression of miRNAs bearing p53 family
binding sites. Mutation is the leading cause of p53 dys-
function in serous ovarian carcinoma, as 60–70% of
serous ovarian cancers are known to have TP53 mutations
(48,49), which in general ablate the ability of p53 to
transactivate its target genes. However, because mutations
to TP53 can result in a dominant negative protein that
alters the activity of the other p53 family members, we
examined whether TP53 mutational status affects expres-
sion of miRNAs overexpressed in ovarian carcinoma.
Somatic mutation data for ovarian carcinomas in TCGA
were not available. We therefore determined the p53
mutation status of the 16 ovarian carcinoma specimens
that we previously used for identifying differentially ex-
pressed miRNAs. We sequenced all coding and ﬂanking
regulatory regions for exons 4-10 of TP53, which include
mutation hotspots and also coincide with the most highly
conserved region of the gene (50). We found
non-synonymous TP53 mutations accompanied by loss
of the wild-type allele in 9 out of our 16 ovarian carcinoma
specimens (Supplementary Table S10). Comparing the ex-
pression of miRNAs in the TP53 mutant versus wild-type
specimens demonstrated no signiﬁcant difference in the
expression of the 17 overexpressed miRNAs that are
encoded within the 15 overexpressed loci with p53
binding sites (Supplementary Figure S1). While these
results do not exclude p53 as a possible driver of
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Figure 2. Expression of miRNAs with TF binding sites is correlated
with TF expression in TCGA ovarian carcinoma specimens.
(A–D) Data from 253 TCGA serous ovarian carcinomas were used
to calculate Pearson correlations between expression of the indicated
TFs and expression of 447 miRNAs. Boxplots show the correlations
using mRNA expression data from two TP53 probes (A), three TP63
Figure 2. Continued
probes (B), four TP73 probes (C), and two EGR2 probes (D). miRNAs
were classiﬁed by the presence (+) or absence ( ) of the indicated TF
binding site in the miRNA promoter. For each probe, t-tests were used
to compare mean correlation values of the two miRNA classes, and
P-values computed from the t-tests are shown. Probes: TP53-1
(NM_000546_2_2048), TP53-2 (A_23_P26810), TP63-1 (A_23_
P91979), TP63-2 (A_32_P114473), TP63-3 (A_32_P114475), TP73-1
(A_23_P74078), TP73-2 (A_23_P74081), TP73-3 (A_24_P413470),
TP73-4 (NM_005427_1_1638), EGR2-1 (A_23_P46935) and EGR2-2
(A_23_P46936).
504 Nucleic Acids Research, 2012,Vol. 40,No. 2differential miRNA expression, this analysis suggests that
p53 is not the primary regulator of these miRNAs in
ovarian carcinoma.
p73 and p63 as putative positive regulators of miRNA
expression in ovarian cancer
Our miRNA expression correlation analyses from TCGA
data suggested that p73, and potentially p63, may drive
the overexpression of miRNAs in ovarian carcinoma
(Figures 2B and C). To identify speciﬁc miRNAs that
may be regulated by p73 or p63 for further study, we
used the P-values from the Pearson correlations to rank
the miRNAs that were overexpressed in ovarian carcin-
oma and contained p53 family binding sites. We found
multiple miRNAs with signiﬁcant positive correlation
with TP73 or TP63 expression (Table 2). A complete list
of miRNAs showing positive correlations (Pearson correl-
ation coefﬁcient >0.25 and P<0.05) with all p73 and p63
probes is provided in Supplementary Tables S11 and S12.
To provide a biologically relevant reference for inter-
preting these correlation values, we also determined the
correlations of 88 host gene-intronic miRNA pairs using
the same data set of 253 TCGA samples. Intronic
miRNAs (i.e., lying in host genes on the same strand)
are generally co-transcribed with their host gene and
therefore show strong correlations in expression with
their host gene. Among miRNA-host gene pairs
analyzed by the same criteria (correlation coefﬁcients
>0.25 and P<0.05), host gene-intronic miRNA pairs
showed an average correlation of 0.37 ( 0.16). The cor-
relations between the expression of p73 and p63 and
miRNAs in Table 2 range between 0.25 and 0.39, and
thus reﬂect a similar magnitude of correlation coefﬁcients
as observed with the host gene-intronic miRNA
correlations.
p73 and p63 directly regulate miR-200 transcription
To experimentally validate our computational predictions,
we examined the transcriptional regulation of the miR-200
family of miRNAs. Expression of all ﬁve members of the
miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141 and miR-429) was positively correlated with
p73 and p63 (all with P<2.2 10
 5), with correlation co-
efﬁcients ranging from+0.318 to+0.389 for p73, and from
+0.263 to+0.322 for p63 (Table 2). Our previous work has
implicated the miR-200 family in ovarian carcinoma
pathogenesis (51), and the miR-200 family has a
well-established role in governing EMTs and repressing
tumor-initiating cells (i.e. cancer stem cells) (18–20,22) in
a variety of other cancer contexts.
The miR-200 family miRNAs are transcribed from two
chromosomal clusters: miR-200b/a/429 from chromosome
1, and miR-200c/141 from chromosome 12. The pro-
moters of both miR-200 clusters contain p53 family
binding sites. We ﬁrst tested whether the predicted p53
family binding sites in the miRNA promoters modulate
miR-200 transcription by employing a luciferase reporter
system. We cloned a 2-kb fragment of the miR-200b/a/429
promoter, which contains one predicted p53 family
binding site, upstream of the luciferase gene in the
pGL3-Enhancer vector. Similarly, we also produced a
miR-200c/141 promoter construct by cloning a 1.5-kb
region of the miR-200c/141 promoter containing two pre-
dicted p53 binding sites into the vector. We then generated
mutant versions of each promoter construct by mutating
the consensus nucleotides in each predicted p53 family
binding site, with the miR-200c/141 mutant promoter
featuring mutations at both of the two predicted binding
sites (Figure 3A). We transfected the wild-type and
mutated constructs into 2008 ovarian carcinoma cells.
Transfection with the wild-type promoter constructs led
to increased luciferase activity as compared to the empty
Table 2. Correlations between TP73 or TP63 and miRNA expression
in TCGA ovarian carcinomas
miRNA Correlation P-value
TP73
miR-107 0.389 1.39E-10
miR-200a 0.389 1.47E-10
miR-29c 0.383 2.77E-10
miR-23a 0.373 8.72E-10
miR-24 0.371 1.17E-09
miR-200c 0.364 2.36E-09
miR-141 0.355 6.12E-09
miR-30c 0.348 1.30E-08
miR-29b 0.346 1.57E-08
miR-429 0.337 4.03E-08
miR-103 0.332 6.62E-08
miR-200b 0.318 2.31E-07
miR-28-5p 0.303 9.31E-07
miR-30e 0.303 9.41E-07
miR-212 0.302 9.77E-07
miR-93 0.301 1.06E-06
miR-7 0.295 1.85E-06
miR-106b 0.291 2.46E-06
let-7c 0.289 2.88E-06
miR-20a 0.284 4.62E-06
miR-130a 0.278 7.05E-06
miR-34a 0.276 8.11E-06
miR-27a 0.274 9.62E-06
miR-135b 0.271 1.25E-05
miR-219-5p 0.266 1.77E-05
miR-19a 0.259 3.02E-05
TP63
miR-200a 0.322 1.64E-07
miR-29c 0.320 1.91E-07
miR-30e 0.316 2.94E-07
miR-30c 0.311 4.50E-07
miR-107 0.310 5.06E-07
miR-429 0.294 1.99E-06
miR-141 0.293 2.09E-06
miR-24 0.287 3.50E-06
miR-103 0.283 4.66E-06
miR-29b 0.278 7.10E-06
miR-200c 0.275 9.19E-06
miR-200b 0.263 2.20E-05
miR-93 0.257 3.57E-05
Correlation coefﬁcients for expression of miRNAs with TP73 expres-
sion and TP63 expression across 253 TCGA ovarian carcinomas were
calculated. MicroRNAs listed showed positive correlation coefﬁcients
>0.25, P<0.05 and contain p53/p63/p73 binding sites in their pro-
moters. MicroRNAs are ranked in order of increasing P-value
(unadjusted). The miR-200 family miRNAs, indicated in bold, had sig-
niﬁcant positive correlations with TP73 and TP63 expression.
Correlation coefﬁcients shown were calculated using representative
probes for TP73 (A_23_P74081) and TP63 (A_32_P114473).
Nucleic AcidsResearch, 2012, Vol.40,No. 2 505vector lacking a promoter, indicating that the minimal
miR-200 promoters were functional (data not shown).
To determine if the p53 family binding sites contribute
to promoter activity, we compared the luciferase activity
of the wild-type versus mutated promoters (Figure 3B).
We found that mutation of the p53 binding sites of the
miR-200b/a/429 and miR-200c/141 promoters each re-
sulted in an  40% decrease in luciferase activity
(P<0.003, t-test), consistent with the notion that members
of the p53 family directly regulate miR-200 transcription.
We next sought to determine which p53 family members
are physically associated with the miR-200 promoters in
ovarian carcinoma cells. We performed chromatin
immunoprecipitations on the 2008 cell line using anti-
bodies directed against p53, p63 or p73, as well as
normal IgG as a control for non-speciﬁc binding. We
did not ﬁnd enrichment of p53 at several known targets,
including p21 and MDM2, nor at the miR-200 promoter
regions, which is consistent with western blots revealing
that 2008 cells do not express stable p53 protein (data not
shown). In the p73 and p63 immunoprecipitations,
however, we found a strong enrichment of the
miR-200b/a/429 p53 family binding site relative to the
IgG control (Figure 3C and D). The levels of enrichment
were similar to those seen at the p21 promoter, a known
transcriptional target of the entire p53 family (46,52). As a
further negative control for non-speciﬁc enrichment, we
assayed the immunoprecipitates for a region 1-kb down-
stream of the 30-end of miR-429, the last miRNA of the
miR-200b/a/429 cluster. No enrichment was found at this
control region, indicating that we were speciﬁcally enrich-
ing the promoter of the miR-200b/a/429 locus. When the
locus on chromosome 12 corresponding to the miR-200c/
141 promoter was analyzed in the p73 and p63 chromatin
immunoprecipitates, no enrichment was observed com-
pared to the IgG control (data not shown). Although
such negative results are difﬁcult to interpret, this obser-
vation may be a false negative due to the limitations of the
sensitivity of chromatin immunoprecipitation, such as the
limited set of promoter regions assayed by qPCR as well
as potentially limited antibody accessibility related to
chromatin structure or interference from transcriptional
co-factors. As an additional negative control, we assayed
the promoter of miR-29a/b-1, which is overexpressed in
ovarian carcinomas yet in our computational analysis
was not found to have p53 family TF binding sites. Our
Wild-type:  GGAGGTGCCCGTGGCTGGCG      GGGCTCACCAGGAAGTGTCC
Mutant:      GTAGGATCGCCTGTATTAAG      GGGATATCGAGGATATTACC
Luciferase
miR-200c/141 promoter (1.5kb)
Wild-type:  GAACCTGTCGGGGCAGGTAA
Mutant:      GAAACATTCGGTTAATTAAA
Luciferase
miR-200b/a/429 promoter (2.0kb)
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Figure 3. p73 and p63 directly regulate transcription of the miR-200 miRNA families. (A) Schematic of the miR-200c/141 and miR-200b/a/429
promoter fragments cloned upstream of the luciferase gene in the pGL3-Enhancer vector. To generate a mutant version of each promoter, the p53
family consensus binding sites were mutated at the nucleotides shown in bold. (B) Activity of the indicated mutant and wild-type miR–200 promoter
constructs transfected into 2008 ovarian carcinoma cells. Promoter activity is expressed relative to the wild-type construct for each promoter, and
bars represent the mean relative activity SD of four replicates. Asterisk indicates P<0.003, t-test. (C and D) Chromatin immunoprecipitation of
p73 (C) and p63 (D) from 2008 cells. qPCR was used to assess the enrichment of the indicated regions relative to an IgG control chromatin
immunoprecipitation. Enrichment of the p53 family binding sites and negative control regions 1kb30 to the miRNAs at the miR–200b/a/429 loci are
shown. Enrichment of the p21 promoter served as a positive control. Bars represent mean enrichment SD of technical replicates from a repre-
sentative experiment that was repeated three times.
506 Nucleic Acids Research, 2012,Vol. 40,No. 2chromatin immunoprecipitation analysis found no enrich-
ment of p63 or p73 at the miR-29a/b-1 promoter
(Supplementary Figure S2). Taken together, our results
demonstrate that both p73 and p63 associate with the
miR-200b/a/429 promoter and may also contribute to
the expression of the miR-200c/141 locus in ovarian
carcinoma.
DISCUSSION
Our study demonstrates how an integrative computational
approach can take advantage of increasingly comprehen-
sive genomic proﬁling data sets to understand the tran-
scriptional regulation of miRNAs. Although miRNA
transcriptional regulation mechanisms have been investi-
gated for speciﬁc miRNAs in the past, genome-scale
studies have been limited, partially due to the lack of
well-annotated miRNA primary transcripts and their cor-
responding transcriptional start sites. MicroRNAs are
excised through a series of processing steps from primary
transcripts, which are highly variable in length and can be
several kilobases long; identifying the TSS for miRNAs at
a genome scale is therefore not trivial. Although experi-
mental methods using chromatin signatures to identify
miRNA promoters have been useful in identifying ap-
proximate locations of miRNA TSS in some cases
(53,54), such approaches have their limitations because
miRNA expression is highly tissue speciﬁc and therefore
experimental data applies to a relatively limited subset of
miRNAs in speciﬁc cell line or tissue contexts. Our
genome-wide approach relies heavily on transcript infor-
mation derived from ESTs, both from EST clusters
(AceView) and from ESTs derived from a common clone,
to provide transcript-based evidence for deﬁning the TSS
of intergenic miRNAs. AceView is one of the most com-
prehensive assemblies of human transcriptome data,
drawing cDNA sequences from dbEST, Genbank and
RefSeq and representing a broad panel of tissue and cell
type contexts. There are currently more than 8 million
ESTs in dbEST and notably approximately 2 million 50
capped ESTs in Genbank submitted by Kimura et al. (55).
An important aspect of our study, therefore, is the
genome-wide deﬁnition of presumptive miRNA TSS and
promoters using such data, which provides a resource for
further investigations of miRNA transcriptional
regulation.
The key biological ﬁnding of this work is the identiﬁca-
tion of the p63 and p73 TFs as signiﬁcant activators of
miRNA overexpression in ovarian carcinoma. We found
conserved TF binding sites for the p53/p63/p73 family
upstream of 17 miRNA loci overexpressed in serous ovar-
ian carcinoma, suggesting p63 and/or p73 may coordi-
nately regulate an ensemble of miRNAs that could
signiﬁcantly modify the cellular gene expression landscape
via repression of a cohort of mRNA targets. We also
observed an overrepresentation of conserved EGR2
binding sites upstream of miRNA loci overexpressed in
ovarian carcinoma, with 10 overexpressed miRNA loci
containing EGR2 binding sites. In the TCGA ovarian
carcinoma data set, EGR2 expression was signiﬁcantly
negatively correlated with the expression of miRNAs
containing EGR2 binding sites. EGR2 has been suggested
to be a tumor suppressor, based on the fact that it is fre-
quently underexpressed in human cancers (including ovar-
ian) and cancer cell lines (56,57). We hypothesize that the
10 miRNA loci mentioned above are normally repressed
by EGR2, but that decreased EGR2 expression in ovarian
carcinoma leads to their overexpression.
It is important to note that both p63 and p73 can be
expressed as multiple isoforms that were not distinguish-
able on the expression platforms involved in this study.
The isoforms of p63 and p73 can be divided into two
classes: transactivating TAp63/TAp73 isoforms and the
inhibitory Np63/Np73 isoforms. In ovarian carcin-
oma, multiple inhibitory isoforms of p73 and p63 are
overexpressed and can be associated with poor prognosis
(58,59). In contrast, transactivating TAp73 increases the
response rate to chemotherapy in BRCA-1-associated
ovarian carcinoma (60). We hypothesize that p73 and
p63 may drive the expression of multiple miRNAs that
contribute to tumor aggressiveness and/or treatment
response. For instance, low levels of miR-200 family
miRNA expression are associated with poor treatment
response in ovarian carcinoma (61); thus, TAp73-
mediated activation of miR-200 could serve as a mechan-
ism for increased sensitivity to chemotherapy. Future
studies will be required to determine the role of speciﬁc
isoforms of p73 and/or p63 in determining miRNA tran-
scription in ovarian carcinoma.
In experimental validation of the pipeline predictions,
we focused on the miR-200 family because of its import-
ant roles in tumor development and progression.
Members of the miR-200 family inhibit EMT and suppress
tumor invasion by directly repressing the TFs Zeb1 and
Zeb2 (18–20). Additionally, the miR-200 family has been
shown to repress Bmi1 and Suz12, two essential compo-
nents of polycomb repressor complexes that are respon-
sible for the maintenance of tumor-initiating cells (21,22).
Previous work on miR-200 regulation has largely focused
on mechanisms of repression, including transcriptional in-
hibition and epigenetic modiﬁcations (18,62,63); mechan-
isms of transcriptional activation of this miRNA family
are not well-understood. Our results with p63 and p73
shed light onto positive transcriptional regulation of the
miR-200 family miRNAs, which has potential therapeutic
value in the development of approaches aimed at modify-
ing miR-200 family miRNA expression for the treatment
of diverse forms of human cancer.
Although our work focused on miR-200 transcriptional
regulation by p73 and p63, recent studies have identiﬁed
different mechanisms by which the p53 family can
modulate miR-200 expression. p63 can serve as a tran-
scriptional regulator of Dicer to modulate miRNA matur-
ation, including processing of the miR-200 family (64).
Given our observation of p63 binding to the miR-200b/
a/429 promoter, these studies suggest that p63 can act
both directly and indirectly to alter miRNA expression,
although the mechanism may be cellular context-
dependent. Additionally, a recent report found that in
mammary epithelial cells, p53 serves as a transcriptional
activator of miR-200c, but not of the miR-200b/a/429
Nucleic AcidsResearch, 2012, Vol.40,No. 2 507cluster (17). In ovarian carcinomas, TP53 is commonly
mutated and thus unlikely to drive the overexpression of
miR-200 that we detected in our samples; however, TP53
mutations can frequently yield dominant negative proteins
that interfere with the actions of p63 and p73 through
promoter competition and through the formation of
inactive heterotetrameric complexes (65). Although we
did not ﬁnd a relationship between the TP53 mutational
status of ovarian carcinomas and their expression of
miRNAs with p53 family binding sites, we cannot
exclude the role of p53 in the transcriptional regulation
of the miR-200 family. In contrast, our results indicate
that p63 and p73 are involved in overexpression of this
miRNA family in ovarian carcinoma. Taken together with
the report of p53-driven miR-200c expression in
mammary epithelial cells, our study suggests that cellular
context determines the relative importance of different p53
family members on the transcriptional activation of the
miR-200 family.
Through our integrative analysis, we identiﬁed tran-
scriptional mechanisms that govern miRNA expression
in ovarian carcinoma and also found novel activators of
miRNAs implicated in tumorigenesis. Our results indicate
that p73 and potentially also p63 contribute to broad
dysregulation of miRNA expression in ovarian carcin-
oma. Although we have directed our analysis here
toward ovarian cancer, our approach can be broadly
applied to other cancer types (e.g., TCGA data sets are
expected to expand to include nearly 25 cancer types), or
any biological state(s) in which mRNA and differential
miRNA expression data are available (e.g., expression
proﬁles across stages of development or across different
cell differentiation states). Because different cancer and
tissue types show unique mRNA and miRNA expression
patterns, utilizing our computational pipeline with other
systems may reveal distinct TFs that regulate miRNA
activity in varied biological contexts.
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